Crinetics Pharmaceuticals (CRNX) Accumulated Expenses (2017 - 2025)
Crinetics Pharmaceuticals has reported Accumulated Expenses over the past 9 years, most recently at $35.6 million for Q4 2025.
- For Q4 2025, Accumulated Expenses rose 23.16% year-over-year to $35.6 million; the TTM value through Dec 2025 reached $35.6 million, up 23.16%, while the annual FY2025 figure was $35.6 million, 23.16% up from the prior year.
- Accumulated Expenses for Q4 2025 was $35.6 million at Crinetics Pharmaceuticals, up from $32.4 million in the prior quarter.
- Over five years, Accumulated Expenses peaked at $35.6 million in Q4 2025 and troughed at $3.2 million in Q1 2021.
- A 5-year average of $14.3 million and a median of $11.0 million in 2022 define the central range for Accumulated Expenses.
- Biggest five-year swings in Accumulated Expenses: surged 137.03% in 2024 and later grew 6.97% in 2025.
- Year by year, Accumulated Expenses stood at $6.6 million in 2021, then soared by 37.84% to $9.1 million in 2022, then soared by 59.86% to $14.5 million in 2023, then soared by 98.99% to $28.9 million in 2024, then increased by 23.16% to $35.6 million in 2025.
- Business Quant data shows Accumulated Expenses for CRNX at $35.6 million in Q4 2025, $32.4 million in Q3 2025, and $21.8 million in Q2 2025.